Assessment of rheumatological arthritis diseases
Rheumatist arthritis is a whole-of-the-body immunopathic disease that begins with a danger to the joint, clinically manifested in joints and extra joints, joints in the form of morning stagnating, joint swelling, joint pain, joint malformations and functional impairments, and extra joints in the form of rheumatism, heart, kidney, lung, blood, nerve, and so on.
The principle of treatment for rheumatism is early, standardised and regularly monitored follow-up, with the goal of achieving disease mitigation or low disease activity, i.e., standard treatment, with the ultimate aim of controlling the condition, reducing the rate of disability, improving the quality of life of patients, early diagnosis, early treatment, effective control of early intervention and even a complete reduction of symptoms.
National and international authorities and experts have made it clear that the target target for the treatment of rheumatism is to achieve disease mitigation or low disease activity.
Timely disease surveillance can significantly reduce the progress of joint damage by monitoring and adjusting the use of medicines once a month, as opposed to one every three months, further reducing disease activity, slowing radiology and improving the functioning and quality of life of the body.
The disease assessment is divided into:
Clinical assessment: Laboratory examination: CRP, ESR, RF, etc. Visual examination Disease activity assessment.
Patient Self-Assessment: The clinical assessment focuses more on changes in joint symptoms, neglecting the overall state of health of the patient.
Laboratory blood tests during the monitoring of rheumatitis: determination of chronic pathological anaemia (the patient usually has mild and moderate anaemia); rapid increase in blood sedation rates of rheumatism (ESR); C Reacting Protein (CRP) and serum IgG, IgM, IgA Increase of rheumatist factors, anti-cyclogualium amino acid antibodies, anti-orthodox anti-protein (AKA) and anti-nucleary nucleus (APF) anti-reparated mercuric melan acid (MCV) antibodies, p68 antibodies, and anti-mealycerin (ACF) antibodies, diagnosis and diagnosis.
There can be significant progress in joint damage within three months for patients with moderate/high disease activity.
Frequency of monitoring/attendance during rheumatitis treatment:
1. If the target is not met, it is recommended that the disease activity be monitored once every 1-3 months.
2. Initial treatment and medium/high disease activity with a frequency of 1 per month.
3. Treatment of those who have reached the target is recommended to be monitored once every 3-6 months.
The treatment of rheumatism is therefore aimed at meeting standards, determining whether or not it is primarily dependent on an assessment of the disease, including clinical assessments and patient self-assessments, which include laboratory blood tests, visual examinations and assessment of disease activity. Patient self-assessments are usually assessed on a scale, the higher the score, the worse disease control, the frequency of disease assessment and monitoring, timely medical access and ensuring the timely adjustment of drugs and long-term disease control.
Rheumatism arthritis
